Heterocyclic Building Blocks-quinoxaline

6924-66-9,6924-66-9, Quinoxaline-5-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 1: N-Q-chlorophenvDquinoxalme-S-carboxamideA solution (0.1 M) of quinoxaline-5-carboxylic acid in CH2Ck was treated with DIPEA (2.2 eq.), 3- chloroaniline (1.1 eq.) and HATU (1.1 eq.). The reaction mixture was stirred at RT overnight. The solution was diluted with EtOAc and the organic phase was washed with aqueous NaHC?3 (saturated solution) and dried. Evaporation of the solvent gave a crude that was washed with MeCN and filtered off affording (93%) the title compound as a solid; MS (ES+) m/z 284, 286 (M+H)+.

The synthetic route of 6924-66-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA; WO2007/28789; (2007); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1204-75-7, 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

3-Hydroxy-2-quinoxalinecarboxylic acid (3.00 g, 15.8 mmol) was dissolved in DMF (50 mL), followed by addition of 4-dimethylaminopyridine (2.12 g, 17.4 mmol). The reaction mixture was stirred at rt until the 4-dimethylaminopyridine dissolved, at which point N,N?-disuccinimidyl carbonate (4.45 g, 17.4 mmol) was added. The reaction mixture was stirred at rt for 30 min (Check HPLC to confirm reaction completion. If the reaction was not complete, additional 0.1 eq portions of DSC were added until HPLC showed complete conversion). A soln. of N-Boc-ethylenediamine (3.04 g, 19.0 mmol) and triethylamine (2.40 g, 3.30 mL, 23.7 mmol) in DMF (10 mL) was then added, and the reaction was stirred at rt for 1 h (check HPLC for reaction completion). The reaction mixture was then poured onto a vigorously stirring soln. of 1M HCl (250 mL). The resulting precipitate was collected by vacuum filtration, washed several times with water, and dried under high-vacuum, giving compound 5 as a yellow solid (5.10 g, 97% yield)., 1204-75-7

The synthetic route of 1204-75-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Ventana Medical Systems, Inc.; Belosludtsev, Yuri; DeGeer, Traci D.; French, Wendy J.; Hao, Junshan; Kelly, Brian D.; Murillo, Adrian E.; Polaske, Nathan W.; (55 pag.)US2018/186821; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

6298-37-9, Quinoxalin-6-amine is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

6298-37-9, c. N-(Quinoxalin-6-yl)acetamide A solution of quinoxalin-6-amine (14.0 g, 0.97 mol) in acetic anhydride (120 mL) was stirred at 100 C. for 1 h. Excess acetic anhydride was removed under reduced pressure. To the residue was added 150 mL of saturated aqueous sodium bicarbonate solution. The mixture was extracted with DCM (3*150 mL), and the combined organic layers were dried over sodium sulfate and concentrated under reduce pressure to give N-(quinoxalin-6-yl)acetamide as a yellow solid (8.4 g, yield 47%). ESI MS: m/z 188.1 [M+H]+.

The synthetic route of 6298-37-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Sunovion Pharmaceuticals Inc.; US2012/178748; (2012); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,50998-17-9

To a solution of 11d (30 mg, 101 mumol), 6-bromoquinoxaline (31.4 mg, 150 mumol), Bu4NOAc (60.2 mg, 200 mol) and Pd(OAc)2 (3.37 mg, 15 mol) in NMP (0.5 mL). The reaction mixture was stirred for 9 h at 100 oC and cooled to room temperature. The mixture was concentrated under reduced pressure, diluted with water and extracted with EtOAc (3 ¡Á 5 mL). The EtOAc solution was washed with brine (5 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (1:1 hexane/EtOAc) to afford the compound 12c (5.1 mg, 12%) as a yellow solid. TLC: Rf 0.25 (1:1 hexane/EtOAc). mp: 157-159 oC. 1H-NMR (400 MHz, CDCl3) delta 8.89 (d, 1H, J = 1.6 Hz), 8.85 (d, 1H, J = 1.6 Hz), 8.13 (d, 1H, J = 8.8 Hz), 8.08 (d, 1H, J = 2.0 Hz), 7.80 (dd, 1H, J = 8.8 Hz, J = 2.0 Hz), 7.73 (t, 1H, J = 8.0 Hz), 7.63 (d, 1H, J = 8.0 Hz), 7.12 (d, 1H, J = 8.0 Hz), 6.75 (d, 1H, J = 2.0 Hz), 6.40 (t, 1H, J = 2.0 Hz) 3.64 (s, 6H), 2.18 (s, 3H). 13C-NMR (100 MHz, CDCl3) delta 161.0, 158.3, 149.0, 146.0, 145.9, 145.8, 143.0, 142.6, 139.1, 132.7, 132.4, 132.1, 131.6, 131.0, 129.5, 123.7, 115.7, 105.7, 101.1, 55.4, 23.8.HRMS (ESI) calcd. for C24H21N6O2 (M+H): 425.1721; found 425.1724.

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Li, Fei; Park, Yunjeong; Hah, Jung-Mi; Ryu, Jae-Sang; Bioorganic and Medicinal Chemistry Letters; vol. 23; 4; (2013); p. 1083 – 1086;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.130345-50-5,Quinoxaline-6-carbaldehyde,as a common compound, the synthetic route is as follows.

To a solution of quinoxaline-6-carbaldehyde (0.96 g, 6.1 mol; see Example 4(a) above) in a mixed solvent of THF (40 mL) and iPrOH (10 mL), was added (phenylamino-(2- trifluoromethyl-pyrimidin-4-yl)-methyl)-phosphonic acid diphenyl ester (3.0 g, 6.1 mmol; see Example 3(b) above) and Cs2CO3 (2.64 g, 8 mmol). It was stirred at room temperature overnight and then treated with 3N HCl (10 mL) for 1 hour. The reaction mixture was then diluted with methyl t-butyl ether and extracted with IN HCl twice. The combined aqueous layers were neutralized with 30% aqueous KOH to pH of ca. 8, then extracted with ethyl acetate (3x). Organic layers were dried over MgSO4 and concentrated to yield a dark orange oil, which was purified on silica gel column with EtOAc/hexane (4:1) to give 2-quinoxalin-6-yl-l-(2- trifluoromethyl-pyrimidin-4-yl)-ethanone (1.67 g) as a yellow solid. LC-MS/ES+: M+l: 319.39. 1H NMR (300 MHz, CDCl3), delta 9.08 (d, IH), 8.75 (m, 2H), 8.03-7.96 (m, 3H), 7.67 (dd, IH), 4.71 (s, 2H)., 130345-50-5

130345-50-5 Quinoxaline-6-carbaldehyde 763958, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; BIOGEN IDEC MA INC; WO2006/26305; (2006); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, Example 13l-ethyl-3-(5-(quinoxalin-6-yl)-4-(4-(trifluoromethyl)thiazol-2-yl)pyridin-2-yl)ureaA reaction mixture of l-ethyl-3-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-4-(4- (trifluoromethyl)thiazol-2-yl)pyridin-2-yl)urea (Intermediate 12, 100 mg, 0.23 mmol), 6- bromoquinoxaline (43.0 mg, 0.21 mmol),Tetrakis (23.75 mg, 0.02 mmol), and cesium carbonate (73.7 mg, 0.23 mmol) in dioxane and water was prepared. The reaction mixture was degassed with nitrogen for 15 minutes and then heated to 100 0C for 1 h. The reaction mixture was partitioned between methylene chloride and water. The organic layer was washed with saturated sodium chloride, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by flash column chromatogrpahy (silica, 15:1 methylene chloride/methanol) gave 44 mg of desired product.MS (ESP): 445 (M+ 1) for C20H15F3N6OS.1H NMR (300 MHz, DMSO-J6): 1.12 (t, J = 7 Hz, 3H), 3.24 (m, 2H), 7.23 (m, IH), 7.43 (m, IH), 8.04 (m, IH), 8.21 (m, IH), 8.36 (m, IH), 8.55 (m, IH), 9.02 (br s, 2H), 9.36 (s, IH), 9.52 (s, IH).

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; BIST, Shanta; EAKIN, Ann; SHERER, Brian; ZHAO, Shannon; WO2011/24004; (2011); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

2213-63-0, 2,3-Dichloroquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of sodium (1 mmol) and an alcohol (3 mL) was stirred for 15 min at room temperature. Then 2,3-dichloroquinoxaline (1 mmol) was added to the mixture until the complete consumption of the starting materials (monitored by TLC). After evaporation of the solvent, the resulting precipitate was washed with H2O; it did not require any further purification., 2213-63-0

The synthetic route of 2213-63-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Keivanloo, Ali; Soozani, Atena; Bakherad, Mohammad; Mirzaee, Mahdi; Rudbari, Hadi Amiri; Bruno, Giuseppe; Tetrahedron; vol. 73; 12; (2017); p. 1633 – 1639;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.91-19-0,Quinoxaline,as a common compound, the synthetic route is as follows.

91-19-0, A solution of quinoxaline (1) (390mg, 3.0mmol), NBS (390mg, 3.0mmol), and benzoyl peroxide (catalytic amount) in glacial acetic acid (10mL) was heated at reflux temperature for 20h. The reaction was monitored by TLC or 1H NMR spectroscopy. The resulting reaction mixture was allowed to cool to room temperature and the solvent was removed under reduced pressure. The mixture was diluted with a saturated solution of sodium carbonate (10mL) and the mixture was extracted with ethyl acetate (2¡Á25mL). Combined organic layers were washed with water, dried over Na2SO4 and concentrated. 6-Bromoquinoxaline (10) (315mg, 50%) was obtained as a sole product. The reaction was repeated using DMF as a solvent at the same reaction condition and monobromide 10 was obtained in 51% yield.

91-19-0 Quinoxaline 7045, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Article; Ucar, Sefa; E?siz, Selcuk; Da?tan, Arif; Tetrahedron; vol. 73; 12; (2017); p. 1618 – 1632;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

13708-12-8, 5-Methylquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5-Methylquinoxaline (0.180 mL, 1.387 mmol, commercially available from, for example, Sigma-Aldrich), NBS (289 mg, 1.624 mmol), benzoyl peroxide (37 mg, 0.153 mmol) and 1,2- dichloroethane (4 mL) was stirred at 110 C for 2 h. Further portions of NBS (260 mg, 1.461 mmol)and benzoyl peroxide (31 mg, 0.128 mmol) were added and the reaction refluxed for a further 2 h. The solution was concentrated to give 1.1 g of a brown solid which was purified by chromatography on 5i02 (Biotage SNAP 50 g cartridge, eluting with O-100% diethylether/cyclohexane). The desired fractions were concentrated to give 5-(bromomethyl)quinoxaline (310 mg, 0.882 mmol, 63.6 % yield) as a yellow oil.LCMS (2 mm Formic): Rt=0.91 mi [MH] = 223, 225.

13708-12-8, 13708-12-8 5-Methylquinoxaline 61670, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED; ATKINSON, Stephen John; AYLOTT, Helen Elizabeth; COOPER, Anthony William James; DEMONT, Emmanuel Hubert; HARRISON, Lee Andrew; HAYHOW, Thomas George Christopher; LINDON, Matthew J; PRESTON, Alexander G; SEAL, Jonathan Thomas; WALL, Ian David; WATSON, Robert J; WOOLVEN, James Michael; (308 pag.)WO2017/37116; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, Description 137; 6-Quinoxalin-6-vlpvrimidin-4-amine; 6-Bromoquinoxaline (210 mg, 1.44 mmol), potassium acetate (141 mg, 1.44 mmol), bis (pinacolato) diboron (383 mg, 1.51 mmol) and [1, 1′- bis (diphenylphosphino) ferrocene] palladium (II) chloride (52 mg, 0.072 mmol) were suspended in dioxane (10 ml) and heated to 100C for 16 hours. 4-Amino-6- chloropyrimidine [WO-A-0245652] (186 mg, 1.44 mmol), [l, 1′- bis (diphenylphosphino) ferrocene]-palladium (II) chloride (52 mg, 0.072 mmol) and 2M Na2CO3 (aq) (2ml) were added and the mixture was heated at 100 oC for a further 16 hours. The mixture was partitioned between EtOAc and water, the aqueous phase was extracted with EtOAc, the combined organic phases were washed (brine), dried (sodium sulfate) and concentrated under reduced pressure. The residue was triturated with EtOAc to give a white solid, which was used in the next step without purification (170 mg).

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; MERCK SHARP & DOHME LIMITED; WO2005/47279; (2005); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider